I n patients with structural heart disease, scar-related ventricular tachycardia (VT) is often associated with hemodynamic instability that precludes detailed entrainment and activation mapping. Furthermore, repetitive inductions of short periods of unstable VT, or even prolonged episodes of otherwise well-tolerated VT, can have a detrimental cumulative effect and expose patients to progressive hemodynamic compromise and end-organ dysfunction. As a result, ablation strategies in patients with scar-VT and significant structural heart disease are often limited to substrate mapping and ablation performed in sinus rhythm. 1 Although this approach seems to be effective for a significant number of postmyocardial infarction patients, it is less applicable to other patient populations, such as those with nonischemic cardiomyopathy, which comprise more than one third of all patients presenting with scar-VT and comprises increasing proportion of scar-VT substrates. A substrate-based ablation strategy (late potentials and pace-mapping) is significantly less effective in patients with nonischemic cardiomyopathy as compared with ischemic cardiomyopathy, because of the relative paucity of putative channels in sinus rhythm. 2 Furthermore, pure substrate-based ablation is considered nonspecific, and VT can recur in up to half of patients despite extensive substrate modification. 1 Finally, patients with VT circuits adjacent to critical structures, such as the coronary artery or phrenic nerve, would also be less than optimal candidates for substrate-based ablation. Despite these limitations, substrate-based ablation is familiar to most operators and avoids the potential negative outcomes associated with prolonged episodes of VT.
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However, entrainment/activation mapping is proof that a targeted isthmus is clinically relevant, may be the only option for certain substrates, and theoretically may require less ablation. Although intravenous vasopressors/inotropes are often used to stabilize blood pressure and cardiac output to allow detailed mapping, they are usually insufficient for mapping fast VT or multiple VTs. 3 Intra-aortic balloon pumps, which are commonly used during VT ablation, augment diastolic pressure and diminish afterload during periods of sinus rhythm but do not provide any significant level of hemodynamic support during VT. 3 As such, there has been an increasing focus on the potential role of percutaneous hemodynamic support during scar-VT ablation. There are currently 3 different percutaneous circulatory support systems, which have been used during scar-VT ablation, including extracorporeal membrane oxygenation, TandemHeart system (Cardiac Assist, Inc, Pittsburgh, PA), and the Impella 2.5 System (Abiomed Inc, Denver, MA). 4 Percutaneous hemodynamic support during VT ablation is intended to maintain cardiac output and systemic perfusion during VT to allow for prolonged arrhythmia mapping, unload the left ventricular during periods of sinus rhythm, and reduce the incidence of acute heart failure permitting a more rapid recovery after the procedure. Although experimental modeling has demonstrated that extracorporeal membrane oxygenation provides the greatest level of hemodynamic support (during fast simulated VT or ventricular fibrillation), the largest amount of cumulative published experience in patients undergoing scar-VT ablation is with the TandemHeart and Impella systems. [5] [6] [7] Initially, small case series demonstrated that using percutaneous support devices during scar-VT ablation was feasible. Later studies, which compared percutaneous left ventricular assist device (pLVAD) support (Impella and TandemHeart) to no pLVAD support, demonstrated that the pLVAD permitted a greater duration of mapping during VT and that more VTs could be terminated during ablation, despite the fact that the pLVAD group had lower left ventricular ejection fraction. 5 However, there was no difference in inducibility at the end of the procedure (between the pLVAD and non-pLVAD groups) and using a pLVAD did not result in a reduction in VT recurrence during follow-up. These findings led some to postulate that pLVAD support is not warranted during scar-VT ablation.
In this issue, Reddy et al 8 have attempted to expand our understanding of the potential benefits of pLVAD-supported scar-VT ablation. In this multicenter observational experience, the authors analyzed the outcomes of 66 patients who underwent scar-VT ablation with either an intra-aortic balloon pump (IABP) (n=22) or with non-IABP hemodynamic support (Impella 2.5 [n=25] or TandemHeart [n=19]). The baseline demographics for the entire cohort, which did not differ between the 2 groups, was similar to other reported scar-VT studies: the mean age of the population was 67±12 years, a majority (70%) had ischemic cardiomyopathy, the mean left ventricular ejection fraction was 28±12%, and the mean follow-up was 12±5 months. In approximately one quarter of the patients, the indication for implantation of the hemodynamic support device was borderline hemodynamic status at baseline, another one quarter received the device for unstable VT, and approximately one half underwent implantation for a low left ventricular ejection fraction (defined as ≤15%). The general ablation strategy primarily focused on entrainment/activation mapping when possible (VT was prematurely terminated if the mean arterial blood pressure dropped to <45 mm Hg). However, if VT could not be tolerated despite maximal mechanical circulatory support, a standard substratebased ablation strategy was undertaken. Acute procedural success was defined as noninducibility of the clinical VT.
The authors have made several observations with regard to the use of pLVADs (either Impella or TandemHeart) during scar-VT ablation: (1) percutaneous hemodynamic support was more likely to afford the opportunity to perform entrainment/activation mapping (82% in the non-IABP group versus 59% in IABP group; P=0.046); (2) more unstable VTs could be mapped with the use of percutaneous support, compared with the IABP (1.05±0.78 versus 0.32±0.48; P<0.001); (3) a greater number of VTs (per patient) could be terminated with ablation with the use of Impella or TandemHeart support, compared with IABP (1.59±1.01 versus 0.91±0.81; P=0.007); (4) the use of hemodynamic support did not alter the acute procedural success (noninducible for clinical VT in 89% versus 86%, non-IABP versus IABP, respectively), the incidence of VT recurrence (42% versus 50%, respectively), or mortality at 1 year (36% in both groups). There were also no differences between the 2 groups with respect to procedural time, total ablation time, complications, length of stay, or use of postprocedural antiarrhythmic drugs.
The strengths of this study include its representative patient population and multicenter experience. The conclusions are similar to a prior study from our group, but this current study includes a larger number of patients and reiterates the aforementioned benefits. 5 But this study does have some important limitations. First, the authors noted that the initial goal of ablation was to make the clinical VT noninducible and further attempts to target easily inducible, nonclinical VTs were at the operators discretion. However, recent data suggest that recurrence rates are significantly lower when noninducibility of any sustained monomorphic VT is achieved. 9 Second, unstable VT was not clearly defined and VT was terminated prematurely for a mean arterial blood pressure <45 mm Hg. However, blood pressure monitoring is not ideally suited for hemodynamic monitoring during VT ablation, particularly in patients receiving continuous flow mechanical assist devices. Using a better measure of tissue perfusion, such as cerebral oximetry (as we have previously reported), might allow the hemodynamic support devices to be used to their full potential. 3, 5 Finally, although the lack of randomization between groups is an understandable and acceptable limitation of the study, the inhomogeneity of hemodynamic support device use among the participating centers is more troubling. That is, although the overall ratio of the non-IABP group to IABP group was 2:1, among the 6 centers contributing data to this study, 3 had markedly different ratios. In 2 centers, the ratios were 4.7:1 and 5.5:1, and the third center enrolled only IABP patients. It is perhaps this heterogeneity of experience that explains the surprising observation that the overall left ventricular ejection faction was actually larger in the non-IABP group (29% versus 25%; P=0.213).
Nonetheless, incorporating pLVAD support during VT ablation is a relatively new approach and, like any novel strategy, requires study and validation. The cumulative data from this and previous studies indicate that pLVAD use is feasible, safe and facilitates mapping and ablation of unstable VT. However, it has not been shown to improve acute or long-term outcomes (as compared with conventional strategies). There are multiple possibilities for this latter observation, including selection bias, heterogeneous substrates, and lack of a standardized/accepted ablation strategy for scar-VT. Although baseline demographics are similar between groups in recent pLVAD studies, sicker patients (as assessed by bedside prognostication and frequently not apparent in baseline demographic variables) are more likely to receive higher levels of hemodynamic support. This has led some to see the glass half-full (pLVAD support permits extended periods of mapping/ablation during VT and prevents a detrimental impact on end-organ function or ventricular filling pressures), whereas others see it as half-empty (extended mapping/ablation during VT with pLVAD support does not alter acute outcomes or recurrence rates). A prospective trial that focuses on a distinct patient population, such as nonischemic cardiomyopathy, a cohort for which substrate mapping/ablation is less effective and for which facilitation of entrainment/activation mapping of unstable VTs may be more meaningful, would increase our understanding of the role of pLVAD support during VT ablation. 2 Additional considerations should include standardized end points of acute success and the ablation strategy, as well as the economic impact of pLVAD use-on the one hand the cost of the device, and on the other, potential cost savings related to reduced hospitalization. Until such a prospective randomized trial is conducted, we will not really know whether the juice (long-term efficacy) is worth the squeeze (pLVAD use), and individual operators will have to decide based on patient and procedural-specific variables whether the associated costs and potential for complications are outweighed by the incremental hemodynamic benefits provided by pLVAD support during VT ablation. 10 
